Torrent Pharmaceuticals is an API and finished-dose manufacturer based in India. It holds 39 active US drug master files and 9 valid CEPs. Its filings concentrate with US FDA, DAV (Vietnam) and NPRA (MY). Its GMP standing is certified by CDSCO (India), EMA and ANVISA (Brazil), among 7 authorities. Its most recent recorded inspection, by US FDA, closed on 23 January 2026 as NAI. Customs aggregates show $358.9M of exports covering 10,151 molecules to 67 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Indrad, United Arab Emirates | Not on file |
| State-Gujarat, United Arab Emirates | Not on file |
| Bavaria, Germany | Not on file |
| Nuremberg, Germany | Not on file |
| Village Bhat, India | Not on file |
| KADI, India | Not on file |
6 further sites are on record.
| Molecule | Regulators | Docs |
|---|---|---|
| Esomeprazole | US FDA | 2 |
| Lamotrigine | EDQM, US FDA | 2 |
| Nebivolol | EDQM, US FDA | 2 |
| Olanzapine | EDQM, US FDA | 2 |
| Repaglinide | EDQM, US FDA | 2 |
| Risperidone | EDQM, US FDA | 2 |
| Sildenafil | EDQM, US FDA | 2 |
| Sitagliptin | EDQM, US FDA | 2 |
| Telmisartan | EDQM, US FDA | 2 |
| Alfuzosin | US FDA | 1 |
| Alogliptin | US FDA | 1 |
| Anagrelide | US FDA | 1 |
| Atorvastatin | US FDA | 1 |
| Candesartan Cilexetil | US FDA | 1 |
| Darifenacin | US FDA | 1 |
| Donepezil | US FDA | 1 |
| Duloxetine | US FDA | 1 |
| Febuxostat | US FDA | 1 |
| Guanfacine | US FDA | 1 |
| Levoketoconazole | US FDA | 1 |
| Lurasidone | US FDA | 1 |
| Montelukast | US FDA | 1 |
| Olmesartan | US FDA | 1 |
| Olmesartan Medoxomil | EDQM | 1 |
| Penciclovir | US FDA | 1 |
| Pramipexole | US FDA | 1 |
| Prucalopride | US FDA | 1 |
| Quetiapine | US FDA | 1 |
| Rabeprazole | US FDA | 1 |
| Rasagiline | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| US FDA | 225 | 3 |
| DAV (Vietnam) | 151 | None |
| NPRA (MY) | 85 | None |
| MCAZ (ZW) | 78 | None |
| CDSCO (India) | 32 | 15 |
| ARCSA (EC) | 23 | None |
| EMA | None | 8 |
| ANVISA (Brazil) | None | 5 |
| ZLG (DE) | None | 4 |
| NAFDAC (NG) | None | 3 |
| TMDA (TZ) | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $66.2M | 42 |
| 2025 | $1.3B | $358.9M | 67 |
| 2024 | $1.3B | $344.8M | 58 |
| 2023 | $1.2B | $310.0M | 58 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.
Choose your molecules and target markets. Torrent Pharmaceuticals comes back tiered against every other supplier able to file there.
Start for freeRanked by shared active ingredients where we have them, otherwise by country and comparable credentials.